<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key processes during mitosis </plain></SENT>
<SENT sid="1" pm="."><plain>Human PLK1 has been shown to be overexpressed in various human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, and elevated levels of PLK1 have been associated with poor prognosis, making it an attractive target for anticancer therapy </plain></SENT>
<SENT sid="2" pm="."><plain>TAK-960 [4-[(9-<z:chebi fb="0" ids="52880">cyclopentyl</z:chebi>-7,7-difluoro-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-N-(1-methylpiperidin-4-yl) <z:chebi fb="0" ids="28179">benzamide</z:chebi>] is a novel, investigational, orally bioavailable, potent, and selective PLK1 inhibitor that has shown activity in several <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines, including those that express multidrug-resistant protein 1 (MDR1) </plain></SENT>
<SENT sid="3" pm="."><plain>Consistent with PLK1 inhibition, TAK-960 treatment caused accumulation of G(2)-M cells, aberrant polo mitosis <z:mp ids='MP_0000002'>morphology</z:mp>, and increased phosphorylation of <z:chebi fb="0" ids="15358">histone</z:chebi> H3 (pHH3) in vitro and in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>TAK-960 inhibited proliferation of <z:e sem="disease" ids="C0346429" disease_type="Neoplastic Process" abbrv="">multiple cancer</z:e> cell lines, with mean EC(50) values ranging from 8.4 to 46.9 nmol/L, but not in nondividing <z:mpath ids='MPATH_458'>normal</z:mpath> cells (EC(50) &gt;1,000 nmol/L) </plain></SENT>
<SENT sid="5" pm="."><plain>The mutation status of TP53 or KRAS and MDR1 expression did not correlate with the potency of TAK-960 in the cell lines tested </plain></SENT>
<SENT sid="6" pm="."><plain>In animal models, oral administration of TAK-960 increased pHH3 in a dose-dependent manner and significantly inhibited the growth of HT-29 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> xenografts </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with once daily TAK-960 exhibited significant efficacy against multiple <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts, including an adriamycin/paclitaxel-resistant <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> and a disseminated <z:hpo ids='HP_0001909'>leukemia</z:hpo> model </plain></SENT>
<SENT sid="8" pm="."><plain>TAK-960 has entered clinical evaluation in patients with <z:e sem="disease" ids="C0877373" disease_type="Neoplastic Process" abbrv="">advanced cancers</z:e> </plain></SENT>
</text></document>